Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

ABSTRACT:

Background

Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to understand antifibrotic prescribing and identify unmet needs in IPF treatment practice.

Methods

Between February and March 2016, respiratory physicians from France, Germany, Italy, Spain, and the UK participated in an online questionnaire designed to collect information on IPF treatment patterns in patients under their care. Patients were categorized as treated (received approved antifibrotics) or untreated (did not receive approved antifibrotics, but may have received other unapproved

SUBMITTER: Maher TM 

PROVIDER: S-EPMC5602932 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature